- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Generic Nolvadex ( Tamoxifen )
Nolvadex (tamoxifen citrate) is a selective estrogen receptor modulator (SERM) indicated for the treatment of estrogen receptor-positive breast cancer, for the adjuvant treatment of early breast cancer following surgery, for the reduction of breast cancer risk in women at high risk, and for the reduction of invasive breast cancer after surgery and radiation for ductal carcinoma in situ (DCIS). In breast tissue, tamoxifen acts as an estrogen antagonist by competitively binding to estrogen receptors, blocking the growth-stimulating effects of estrogen on tumour cells. In other tissues, such as bone and endometrium, it has partial estrogen agonist activity. Tamoxifen is effective only in hormone receptor-positive disease and is not a cytotoxic chemotherapy agent.
Usual adult dose: For adjuvant treatment of early breast cancer, the recommended dose is 20 mg taken orally once daily, or 10 mg taken twice daily, for 5 years. For advanced or metastatic breast cancer, the dose may be increased to 20 mg twice daily (40 mg total daily) in selected patients, although 20 mg once daily is the standard initial dose. For breast cancer risk reduction in high-risk women and for DCIS, the dose is 20 mg once daily for 5 years. Nolvadex may be taken with or without food, and the tablets should be swallowed whole with water. If a dose is missed, it should be taken as soon as remembered unless it is close to the next scheduled dose; two doses must not be taken at the same time. No dose adjustment is required for elderly patients or those with mild renal or hepatic impairment, but caution is advised in severe hepatic impairment. Treatment duration and additional therapy are determined by the oncologist.
Dosage form: Film-coated tablets: 10 mg (white to off-white, round, biconvex) and 20 mg (white to off-white, round or octagonal, biconvex). Available in blister packs or bottles of 30 or 100 tablets.
Onset of action: Steady-state plasma concentrations of tamoxifen are reached after approximately 4 weeks of daily dosing, while the active metabolite N-desmethyltamoxifen reaches steady state after approximately 8 weeks. Clinical benefit in breast cancer, including reduction in recurrence risk and tumour regression, is assessed over months to years of continuous therapy.
Duration of action: The elimination half-life of tamoxifen is approximately 5 to 7 days, and the half-life of the active metabolite is approximately 14 days. The anti-estrogenic effect persists for weeks after discontinuation due to the long half-life, but once-daily or twice-daily dosing is used to maintain continuous receptor blockade.
Alcohol recommendation: No direct interaction between tamoxifen and alcohol has been clearly established. However, excessive alcohol consumption may increase the risk of hot flashes, liver dysfunction, and thromboembolic events, and can impair overall treatment tolerance. Patients should limit alcohol intake and discuss any concerns with their oncologist.
Most common side effects: Hot flashes, vaginal discharge, irregular menstrual bleeding, nausea, fatigue, and mood changes. Menstrual irregularities and hot flashes are common and may be managed with supportive measures. More serious adverse effects include venous thromboembolism (deep vein thrombosis and pulmonary embolism), endometrial hyperplasia, endometrial cancer, and uterine sarcoma. The risk of endometrial cancer is increased approximately 2- to 3-fold in postmenopausal women and requires prompt investigation of any abnormal vaginal bleeding. Other effects include cataracts, fluid retention, and bone pain. In premenopausal women, tamoxifen may induce ovarian hyperstimulation and increase the risk of pregnancy; effective non-hormonal contraception is required. Tamoxifen is contraindicated during pregnancy due to the risk of fetal harm. Because tamoxifen is metabolized by CYP2D6, concurrent use of strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, bupropion) may reduce its efficacy and should be avoided when possible. Nolvadex is available only by prescription and must be prescribed and monitored by a healthcare professional experienced in oncology.
Would you like to try Nolvadex (Tamoxifen) without a prescription?
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
